We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
- Authors
Moore, M J; Hamm, J; Dancey, J; Eisenberg, P D; Dagenais, M; Fields, A; Hagan, K; Greenberg, B; Colwell, B; Zee, B; Tu, D; Ottaway, J; Humphrey, R; Seymour, L; National Cancer Institute of Canada Clinical Trials Group
- Abstract
To compare the selective matrix metalloproteinase inhibitor BAY 12-9566 with the nucleoside analog gemcitabine in the treatment of advanced pancreatic cancer.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Vol 21, Issue 17, p3296
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2003.02.098